All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The toxicity caused by off-target binding to the cell surface or secreted proteins is the main cause of drug development failure. Assessing the toxicity of drug candidates can help reduce risk through a more informed safety assessment and save significant time and resources by allowing the early failure of adverse drugs. Creative Biolabs's cell microarray screening can be applied to the understanding of the off-target binding potential of novel biopharmaceutical leads during early development. Our off-target screening data can be used to meet the regulatory submission of clinical studies, which require high confidence in the specificity of new biotherapeutics.
High Specificity
Surfarray™'s low false positive rate ensures that months or years of research are not wasted to chase dead ends when verifying potential target hits. Off-target screening using Surfarray™ cell microarray technology typically reports one or two confirmed interactions, rather than 100 erroneous results often seen by protein microarrays. This saves months of verification and avoids unnecessary groping, which can affect regulatory submissions.
Creative Biolabs is dedicated to helping our worldwide customers shorten the discovery and development time in CAR-T cell therapy. We utilize unrivaled, proprietary drug design, study data, product candidate, advanced project life-cycle management, as well as real-time data to ensure the ideal outcomes.
For more detailed information, please feel free to contact us or directly send us an inquiry.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION